Compare Alphabet Inc Class A (GOOGL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Incyte Corporation — how do they compare? Alphabet Inc Class A trades at $371.41 (market cap $4.52T), while Incyte Corporation trades at $115.92 (market cap $22.99B). The key difference: Alphabet Inc Class A is far larger — about 196.6× Incyte Corporation's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| GOOGL | INCY | |
|---|---|---|
Market Cap | $4.52T | $22.99B |
Sector | Media | Health |
52-Week High | $402.62 | $118.52 |
52-Week Low | $182.97 | $67.38 |
Enterprise Value | $4.49T | $19.01B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) stock trades at $370.92, up 3.17% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $350B in 2024 to $402.8B in 2025 and net income surging 32% to $132.2B. Recent quarterly earnings consistently beat expectations, and the company initiated a dividend in 2026. Analyst sentiment remains overwhelmingly positive with 85% buy ratings and a $431.78 consensus price target, suggesting 16% upside potential.
The outlook for GOOGL appears favorable given strong AI-driven growth in cloud and advertising, expanding profitability margins, and solid cash flow generation. Key risks include regulatory scrutiny of antitrust practices, competitive pressures in AI and cloud services, and potential market volatility affecting tech valuations. The stock's current valuation at 28.29x P/E reflects premium pricing for its growth trajectory.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
